DC-SIGN (CD209) Monoclonal Antibodies – UW60.1 and UW60.2

Biomaterial Description

UW60.1 and UW60.2 are mouse-derived monoclonal antibodies targeting human DC-SIGN (CD209), a C-type lectin receptor expressed on dendritic cells and macrophages. DC-SIGN plays an important role in the innate immune system, acting as a molecular sensor that detects and binds to carbohydrate structures on pathogens and host cells. It recognizes a broad spectrum of pathogens—including viruses, bacteria, and parasites—through carbohydrate-mediated binding, facilitating antigen uptake and immune modulation.

The UW60.1 and UW60.2 antibodies were developed using a His-tagged CD209 fusion protein as immunogen and are validated for high specificity and minimal cross-reactivity. They are available in both unconjugated and PE-conjugated formats, optimized for flow cytometry and immunofluorescence.

Applications

-Flow Cytometry: Quantitative analysis of DC-SIGN+ myeloid populations

-Immunocytochemistry & Immunohistochemistry: Visualization of DC-SIGN in tissue and cell samples

-Pathogen Interaction Studies: HIV, Dengue, Ebola, and SARS-CoV binding assays

-Innate Immunity Research: Characterization of dendritic cell function and trafficking

-Therapeutic Target Validation: Preclinical studies in immunomodulation and vaccine development

Advantages

-High Specificity: Selective binding to human CD209 with minimal off-target effects

-Flexible Formats: Available in unconjugated and PE-conjugated versions for diverse assay platforms

-Validated Performance: Optimized for flow cytometry, ICC/IF, and IHC-P

Distributor Information

Non-Exclusive License available.